NRXP NRx Pharmaceuticals, Inc. Stock Quote

NRXP [NASD]

Index	-	P/E	-	EPS (ttm)	-7.60	Insider Own	1.30%	Shs Outstand	41.73M	Perf Week	-11.20%
Market Cap	573.41M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.39M	Perf Month	-23.24%
Income	-298.50M	PEG	-	EPS next Q	-	Inst Own	4.40%	Short Float	13.78%	Perf Quarter	-27.99%
Sales	-	P/S	-	EPS this Y	-596.10%	Inst Trans	-	Short Ratio	0.46	Perf Half Y	-62.78%
Book/sh	-0.42	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-1.65%
Cash/sh	0.25	P/C	42.79	EPS next 5Y	-	ROE	-	52W Range	8.39 - 76.99	Perf YTD	-56.15%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-86.10%	Beta	0.07
Dividend %	-	Quick Ratio	0.50	Sales past 5Y	-	Gross Margin	-	52W Low	27.53%	ATR	1.67
Employees	2	Current Ratio	0.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.53	Volatility	11.39% 10.59%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.30	Prev Close	10.50
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 16 AMC	Payout	-	Avg Volume	4.91M	Price	10.70
Recom	-	SMA20	-19.50%	SMA50	-22.29%	SMA200	-57.33%	Volume	1,477,751	Change	1.90%

Sep-08-21 07:48AM	NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire
Aug-30-21 08:06AM	NRx Pharmaceuticals Announces New Finding from ZYESAMI (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 PR Newswire
Aug-26-21 06:48AM	NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies PR Newswire
Aug-25-21 09:43AM	What Is The Ownership Structure Like For NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)? Simply Wall St. -12.06%
Aug-24-21 06:48AM	NRx Pharmaceuticals Announces Closing of $30 Million Private Placement PR Newswire +6.53%
Aug-23-21 09:33AM	Participants in High Dose BriLife Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary PR Newswire +15.70%
Aug-19-21 09:17AM	NRx Pharmaceuticals Announces $30 Million Private Placement PR Newswire -15.21%
Aug-18-21 11:53AM	NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19 PR Newswire +11.79%
Aug-16-21 09:32PM	NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update PR Newswire -6.37%
Aug-11-21 04:20PM	NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021 GlobeNewswire -10.41%
Aug-10-21 06:48AM	NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021 PR Newswire +13.04%
Aug-09-21 01:13PM	NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife Vaccine for Covid-19 in Nation of Georgia PR Newswire +14.99%
Aug-04-21 06:48AM	NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI (aviptadil) Inhaler for Respiratory Conditions PR Newswire -8.49%
06:48AM	MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere® Platform PR Newswire
Jul-27-21 11:34AM	NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI (aviptadil) in Nation of Georgia PR Newswire
Jul-22-21 06:48AM	NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval PR Newswire +62.71%
Jul-19-21 06:48AM	NRx Pharmaceuticals Presents Evidence ZYESAMI (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19 PR Newswire +45.31%
Jul-12-21 11:18AM	NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife COVID Vaccine PR Newswire -16.16%
08:45AM	NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial PR Newswire
Jul-06-21 09:20AM	NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI (Aviptadil-acetate) Trial in the Nation of Georgia PR Newswire -8.04%
Jun-15-21 07:33AM	NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI (Aviptadil) Expanded Access Protocol PR Newswire
Jun-09-21 02:50PM	Fertility is not going to be affected in any way by COVID-19 vaccine: Doctor Yahoo Finance Video
Jun-08-21 02:03PM	U.S. response to COVID-19 has a greater list of failures than accomplishments: Expert Yahoo Finance Video -8.89%
Jun-07-21 01:45PM	U.S. should be very concerned as Delta variant spreads in Britain: Doctor Yahoo Finance Video
Jun-01-21 06:28AM	NRx Pharmaceuticals Announces Positive Results for ZYESAMI (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure PR Newswire
May-27-21 06:48AM	NRx Pharmaceuticals Names General H.R. McMaster to Company's Board of Directors PR Newswire
May-26-21 09:29AM	NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma PR Newswire -6.02%

NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience